short list for srx acquisition

HH in notes to preferred clients says Internal estimates of current quarter are tracking in 14-16 million dollar range. This would be 11 cents in eps. NUmbers are being raised again for fifth time in last month. only matter of time until sp catches up will all fundamentals and looking for $6-8 in short term. From that price level acquisition bids can be entertained and their short list is Sanofi, Genentech, Mayne, Cephalon, Roche and Pfizer. Dr Gray wants to cash out as he no longer is with company but owns 17 million shares and he is nearing 70 yrs. due to all late stage trials going on. Recent news that sir spheres is standard of care for liver tumors has added about 200 mmillin in yet to be realized market cap and sp is underpriced by factor of 3-4. Looking for $13-15 in acquisition. My opinion only (and HH). Do your own work. I